Pradžia › Ūmi bifeninė leukemija › Misūris
Ūmi bifeninė leukemija klinikiniai tyrimai Misūris
5 tyrimai dėl Ūmi bifeninė leukemija ieško dalyvių vietose Misūris.
Miestai Misūris
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Washington University in St. Louis School of Medicine, St Louis
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- ir dar 2
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- ir dar 2
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Mercy Hospital of Kansas City, Kansas City
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06177067Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.